The blockade of immune checkpoints in cancer immunotherapy, Nature Reviews Cancer, vol.12, issue.4, pp.252-264, 2012. ,
DOI : 10.1038/nrc3239
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells, Cancer Immunology Research, vol.1, issue.1, pp.32-42, 2013. ,
DOI : 10.1158/2326-6066.CIR-13-0013
PD-1 as a potential target in cancer therapy, Cancer Medicine, vol.16, issue.Suppl., pp.662-73, 2013. ,
DOI : 10.1002/cam4.106
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study, The Lancet Oncology, vol.11, issue.2, pp.155-164, 2010. ,
DOI : 10.1016/S1470-2045(09)70334-1
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting, Cancer, vol.27, issue.22 pt 1, pp.1767-1775, 2010. ,
DOI : 10.1002/cncr.24951
Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival, Annals of Oncology, vol.24, issue.6, pp.1697-703, 2013. ,
DOI : 10.1093/annonc/mdt027
Memorial Sloan- Kettering Cancer Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients (pts) with advanced melanoma treated with ipilimumab, J Clin Oncol, vol.27, 2009. ,
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma, Cancer Immunology, Immunotherapy, vol.369, issue.2, pp.449-58, 2009. ,
DOI : 10.1007/s00262-014-1528-9
Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial, Clinical Cancer Research, vol.16, issue.10, pp.2861-71, 2010. ,
DOI : 10.1158/1078-0432.CCR-10-0569
Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma, Journal for ImmunoTherapy of Cancer, vol.19, issue.3, p.23, 2015. ,
DOI : 10.1186/s40425-015-0070-4
Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients, Science Translational Medicine, vol.6, issue.238, pp.238-70, 2014. ,
DOI : 10.1126/scitranslmed.3008211
Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response, Science Translational Medicine, vol.6, issue.254, pp.254-128, 2014. ,
DOI : 10.1126/scitranslmed.3008918
PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, vol.15, issue.7528, pp.568-571, 2014. ,
DOI : 10.1038/nature13954
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab, Proceedings of the National Academy of Sciences, vol.108, issue.40, pp.16723-16731, 2011. ,
DOI : 10.1073/pnas.1110814108
Mechanisms of regulatory T-cell suppression ??? a diverse arsenal for a moving target, Immunology, vol.178, issue.1, pp.13-22, 2008. ,
DOI : 10.1084/jem.20040165
Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti???Cytotoxic T-Lymphocyte Antigen-4, Journal of Clinical Oncology, vol.23, issue.25, pp.6043-6053, 2005. ,
DOI : 10.1200/JCO.2005.06.205
Ipilimumab Increases Activated T Cells and Enhances Humoral Immunity in Patients With Advanced Melanoma, Journal of Immunotherapy, vol.35, issue.1, pp.89-97, 2012. ,
DOI : 10.1097/CJI.0b013e31823aa41c
Tumor regression and autoimmunity in patients treated with cytotoxic T 36 ,
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25, Cell Research, vol.63, issue.2, pp.208-224, 2015. ,
DOI : 10.4161/cbt.21782
Final Version of 2009 AJCC Melanoma Staging and Classification, Journal of Clinical Oncology, vol.27, issue.36 ,
DOI : 10.1200/JCO.2009.23.4799
Single-Center Experience With Ipilimumab in an Expanded Access Program for Patients With Pretreated Advanced Melanoma, Journal of Immunotherapy, vol.36, issue.3, pp.215-237, 2013. ,
DOI : 10.1097/CJI.0b013e31828eed39
Clinical Significance of Tumor-Infiltrating Lymphocytes in Lung Neoplasms, The Annals of Thoracic Surgery, vol.87, issue.2 ,
DOI : 10.1016/j.athoracsur.2008.10.067
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma, Journal of Translational Medicine, vol.9, issue.1, p.204, 2011. ,
DOI : 10.1097/CJI.0b013e31817fd8f3
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients, Proc. Natl. Acad ,
DOI : 10.1073/pnas.0712237105
CD73: A potential biomarker for anti-PD-1 therapy, OncoImmunology, vol.4, issue.11, p.1046675, 2015. ,
DOI : 10.1158/0008-5472.CAN-14-0957
Signatures of mutational processes in human cancer, Nature, vol.27, issue.7463, pp.415-436, 2013. ,
DOI : 10.1038/nature12477
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity, Cell, vol.160, issue.1-2, pp.48-61, 2015. ,
DOI : 10.1016/j.cell.2014.12.033
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma, New England Journal of Medicine, vol.371, issue.23 ,
DOI : 10.1056/NEJMoa1406498
doi:10.1056/NEJMoa1406498 46 Genomic correlates of response to CTLA-4 blockade in metastatic melanoma, Science, vol.350, issue.80, pp.2189-2199, 2014. ,
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, vol.348, issue.6230, pp.124-128, 2015. ,
DOI : 10.1126/science.aaa1348
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency, New England Journal of Medicine, vol.372, issue.26, pp.2509-2520, 2015. ,
DOI : 10.1056/NEJMoa1500596
Pembrolizumab for the Treatment of Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.372, issue.21 ,
DOI : 10.1056/NEJMoa1501824
Nivolumab in previously untreated melanoma without BRAF mutation, N ,
Pembrolizumab versus Ipilimumab in Advanced Melanoma, New England Journal of Medicine, vol.372, issue.26, pp.2521-2553, 2015. ,
DOI : 10.1056/NEJMoa1503093
Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab, Journal of Translational Medicine, vol.12, issue.Suppl 1, p.8, 2014. ,
DOI : 10.1056/NEJMoa1200690
Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475, ASCO Annual Meeting, pp.5-2014, 2014. ,
Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001 ,
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers, PLOS ONE, vol.348, issue.6230, p.130142, 2015. ,
DOI : 10.1371/journal.pone.0130142.s001
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma, New England Journal of Medicine, vol.373, issue.1, pp.15053111501200210-1056, 2015. ,
DOI : 10.1056/NEJMoa1504030
The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity, Vaccines, vol.3, issue.3, pp.703-732, 2015. ,
DOI : 10.3390/vaccines3030703
Differential regulation of indoleamine 2,3-dioxygenase by lipopolysaccharide and interferon gamma in murine bone marrow derived dendritic cells, FEBS Letters, vol.17, issue.7, pp.1449-56, 2007. ,
DOI : 10.1016/j.febslet.2007.02.073
The Role of IFN-?? and TNF-??-Responsive Regulatory Elements in the Synergistic Induction of Indoleamine Dioxygenase, Journal of Interferon & Cytokine Research, vol.25, issue.1, pp.20-30, 2005. ,
DOI : 10.1089/jir.2005.25.20
Combination Therapy with Anti???CTLA-4 and Anti???PD-1 Leads to Distinct Immunologic Changes In Vivo, The Journal of Immunology, vol.194, issue.3, pp.950-959, 2014. ,
DOI : 10.4049/jimmunol.1401686
An immune-active tumor microenvironment favors clinical response to ipilimumab, Cancer Immunology, Immunotherapy, vol.313, issue.5795, pp.1019-1031, 2012. ,
DOI : 10.1007/s00262-011-1172-6
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma, Cell, vol.165, issue.1, pp.35-44, 2016. ,
DOI : 10.1016/j.cell.2016.02.065
Immune-related adverse events with immune checkpoint blockade: a comprehensive review, European Journal of Cancer, vol.54, pp.139-148, 2016. ,
DOI : 10.1016/j.ejca.2015.11.016
Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab, ASCO Meet. Abstr, p.32, 2014. ,
Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation with colitis., Journal of Clinical Oncology, vol.29, issue.15_suppl, p.29, 2011. ,
DOI : 10.1200/jco.2011.29.15_suppl.2505
Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events, Journal of Translational Medicine, vol.11, issue.1, p.75, 2013. ,
DOI : 10.1186/1479-5876-11-75
Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma, Cancer Immun, vol.10, p.11, 2010. ,
Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade, Clinical Cancer Research, vol.13, issue.22, pp.6681-6689, 2007. ,
DOI : 10.1158/1078-0432.CCR-07-0187
Releasing the Brake on the Immune System: Ipilimumab in Melanoma and Other Tumors, Cancer Biotherapy & Radiopharmaceuticals, vol.25, issue.6, pp.601-614, 2010. ,
DOI : 10.1089/cbr.2010.0865
Ipilimumab: controversies in its development, utility and autoimmune adverse events, Cancer Immunology, Immunotherapy, vol.31, issue.6, pp.823-853, 2009. ,
DOI : 10.1007/s00262-008-0653-8
Clinical experience with ipilimumab 3??mg/kg: real-world efficacy and safety data from an expanded access programme cohort, Journal of Translational Medicine, vol.12, issue.1, p.116, 2014. ,
DOI : 10.1111/nyas.12180
Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature, ASCO Annual Meeting | Abstracts | Meeting Library. Available at, pp.151652-156, 2015. ,